Dilated Cardiomyopathy in Dogs: Causes, Symptoms and Treatment

Dilated cardiomyopathy, commonly referred to as DCM, is one of the most common and serious heart diseases affecting dogs. In this condition, the heart muscle becomes weakened and stretched, causing the chambers of the heart — particularly the left ventricle — to enlarge progressively. As the walls of the heart thin and lose their ability to contract effectively, the heart can no longer pump blood efficiently to meet the body's demands. Over time, this leads to fluid accumulation in the lungs and abdomen, a condition known as congestive heart failure.

"DCM is a condition where early detection truly changes outcomes. A dog diagnosed before symptoms appear — during a routine screening or breeding examination — can live years longer with appropriate treatment compared to a dog diagnosed only when it collapses or develops severe breathing difficulties. I urge owners of at-risk breeds to discuss cardiac screening with their veterinarian." — Dr. Sarah Chen, DVM

DCM is the second most common heart disease in dogs after chronic valvular disease. It primarily affects medium to large and giant breed dogs, with certain breeds carrying a strong genetic predisposition. The disease can develop slowly over months to years, progressing through a prolonged preclinical phase where the heart is deteriorating but the dog appears outwardly healthy. This silent progression is what makes regular screening so important for at-risk breeds.

Understanding DCM is essential for any owner of a predisposed breed. With early detection and modern cardiac treatment protocols, many dogs with DCM can enjoy a good quality of life for months to years after diagnosis. This guide explains the causes, symptoms, diagnosis, and management of this challenging condition.

The causes of dilated cardiomyopathy in dogs are multifactorial, though genetics plays the dominant role in most cases. Understanding the risk factors helps owners and veterinarians identify dogs that need proactive cardiac monitoring.

Genetic Predisposition

The strongest risk factor for DCM is breed. Doberman Pinschers have the highest prevalence, with studies suggesting that 45–63% of the breed may be affected. The disease in Dobermans is particularly aggressive, often progressing rapidly to heart failure or sudden death from fatal arrhythmias. Other highly predisposed breeds include Great Danes, Irish Wolfhounds, Boxers (who develop a unique arrhythmogenic form), Newfoundlands, Saint Bernards, Scottish Deerhounds, and Cocker Spaniels. In most of these breeds, DCM is inherited, though the specific genetic mutations have only been identified in a few.

Nutritional Factors

In recent years, the link between certain diets and DCM has received considerable attention. The US Food and Drug Administration investigated reports of DCM in breeds not typically predisposed to the disease, with many of these dogs eating grain-free diets containing high proportions of legumes (peas, lentils, chickpeas) or potatoes as primary ingredients. While a definitive causal mechanism has not been established, the association led to renewed focus on ensuring adequate taurine and L-carnitine levels in canine diets. Some dogs with diet-associated DCM have shown partial or complete reversal of heart changes when switched to conventional diets and supplemented with taurine.

Other Contributing Factors

Taurine deficiency remains a well-documented cause of DCM, particularly in certain breeds such as American Cocker Spaniels, Golden Retrievers, and Newfoundlands. L-carnitine deficiency has also been implicated in some cases, especially in Boxers. Hypothyroidism may contribute to cardiac dysfunction and should be tested for in dogs diagnosed with DCM. Myocarditis — inflammation of the heart muscle caused by infection (such as Trypanosoma cruzi, the organism causing Chagas disease, or parvovirus) — can lead to a DCM-like condition. Chronic, rapid tachyarrhythmias can also cause secondary DCM through a process called tachycardia-induced cardiomyopathy.

Male dogs are generally more commonly affected than females in most predisposed breeds, and DCM typically develops in middle-aged to older dogs, usually between four and ten years of age.

One of the most challenging aspects of DCM is its prolonged preclinical phase. During this stage — which can last months to years — the heart is enlarging and weakening, but the dog compensates effectively and shows no outward signs of illness. This is why screening is so critical for at-risk breeds.

Preclinical Stage

Dogs in the preclinical phase appear completely normal to their owners. They eat, play, and exercise without obvious difficulty. However, during this time the heart chambers are gradually enlarging, and in some cases dangerous arrhythmias are developing. In Dobermans, sudden death from a ventricular arrhythmia can occur during this otherwise silent phase — roughly 30% of affected Dobermans die suddenly without any prior symptoms. The only way to detect preclinical DCM is through cardiac screening with echocardiography and Holter monitoring.

Early Clinical Signs

As the heart's ability to compensate diminishes, subtle signs begin to appear. These early symptoms are often gradual and easily missed or attributed to ageing:

• Exercise intolerance — your dog tires more quickly on walks or during play, or is reluctant to engage in activities they previously enjoyed
• Increased respiratory rate at rest — a resting respiratory rate consistently above 30 breaths per minute is a significant early warning sign. Learning to count your dog's sleeping respiratory rate is one of the most valuable monitoring tools for owners of at-risk breeds
• Mild cough — particularly noticeable at night or when lying down, caused by fluid beginning to accumulate in or around the lungs
• Subtle lethargy — a general decrease in energy or enthusiasm that may be difficult to distinguish from normal ageing. If you're concerned about changes in your dog's behaviour or energy, trust your instincts and seek veterinary advice
• Mild weight loss or muscle wasting — often noticed over the hindquarters first, this reflects the body's decreased cardiac output and increased metabolic demands

Advanced Symptoms — Congestive Heart Failure

When the heart can no longer compensate, fluid accumulates in the lungs (left-sided heart failure) or the abdomen (right-sided heart failure), and symptoms become unmistakable:

• Laboured or rapid breathing — persistent respiratory distress, particularly at rest or during sleep
• Persistent cough — a soft, moist cough that worsens over time
• Abdominal distension — a pot-bellied appearance caused by fluid (ascites) accumulating in the abdomen
• Collapse or fainting episodes — syncope caused by inadequate blood flow to the brain or dangerous arrhythmias
• Loss of appetite, weakness, and profound lethargy

If your dog shows any signs of breathing difficulty, collapse, or a distended abdomen, seek immediate veterinary attention — these are emergencies.

Diagnosing DCM involves a combination of tests that assess the heart's structure, function, and rhythm. Early screening in predisposed breeds is the most effective strategy for catching the disease before symptoms develop.

Echocardiography

An echocardiogram (cardiac ultrasound) is the gold standard for diagnosing DCM. It allows the veterinary cardiologist to directly visualise the heart chambers, measure wall thickness and chamber dimensions, and assess how effectively the heart is contracting. Key measurements include the left ventricular internal diameter in diastole (LVIDd) and systole (LVIDs), and fractional shortening (FS) — the percentage of change in ventricular diameter between relaxation and contraction. In a normal large-breed dog, fractional shortening is typically 25–40%; in DCM, it drops below 20% and often below 15%. The echocardiogram also detects mitral valve regurgitation, which commonly accompanies DCM as the enlarged heart stretches the valve annulus.

Holter Monitoring

A Holter monitor is a portable electrocardiograph worn for 24 hours that records every heartbeat during normal daily activity. It is particularly important in Dobermans and Boxers, where dangerous ventricular arrhythmias may be the first manifestation of DCM — sometimes occurring months to years before echocardiographic changes appear. More than 50 ventricular premature complexes (VPCs) in 24 hours is considered abnormal in Dobermans and warrants further investigation and monitoring. Annual Holter screening is recommended for Dobermans starting at three to four years of age.

Chest X-rays

Thoracic radiographs reveal heart enlargement (an increased vertebral heart score) and, when present, signs of congestive heart failure — pulmonary oedema (fluid in the lungs) or pleural effusion (fluid around the lungs). Chest X-rays are particularly valuable in emergency presentations and for monitoring response to heart failure treatment.

Blood Tests

Cardiac biomarkers add valuable diagnostic information. Cardiac troponin I (cTnI) is released when heart muscle cells are damaged and can be elevated before echocardiographic changes appear. NT-proBNP is a peptide released in response to heart stretch and volume overload — elevated levels support a diagnosis of heart disease and may help distinguish cardiac from respiratory causes of cough or breathing difficulty. Blood taurine levels should be checked in all dogs diagnosed with DCM, particularly non-predisposed breeds and dogs eating atypical diets. Thyroid function testing is also recommended, as hypothyroidism can worsen cardiac function. Regular veterinary check-ups that include cardiac biomarker screening can help detect DCM in its earliest stages.

While DCM cannot be cured in most cases, modern veterinary cardiology offers effective treatments that can significantly slow disease progression, improve quality of life, and extend survival. Treatment is tailored to the stage of disease — preclinical dogs receive different medications than those in active heart failure.

Preclinical Stage Treatment

The landmark PROTECT study demonstrated that pimobendan — a positive inotrope and vasodilator — significantly delays the onset of congestive heart failure in Dobermans with preclinical DCM, extending the preclinical period by approximately nine months compared to placebo. Pimobendan is now widely recommended for dogs with preclinical DCM once echocardiographic criteria are met. An ACE inhibitor (benazepril or enalapril) may also be started during the preclinical phase. For dogs with significant ventricular arrhythmias, antiarrhythmic medication such as mexiletine or sotalol may be prescribed to reduce the risk of sudden death.

Heart Failure Treatment

When congestive heart failure develops, the treatment protocol expands to include:

• Furosemide (Frusemide) — a loop diuretic that removes excess fluid from the lungs and abdomen, providing rapid relief from breathing difficulty. The dose is adjusted based on respiratory rate and kidney function
• Pimobendan — strengthens heart contractions and reduces the workload on the heart by dilating blood vessels. It is considered essential in the management of DCM-related heart failure
• ACE inhibitors — benazepril or enalapril help reduce fluid retention and counteract harmful neurohormonal activation that worsens heart failure over time
• Spironolactone — a potassium-sparing diuretic and aldosterone antagonist that provides additional neurohormonal blockade and mild diuretic effect

Nutritional Management

Dietary modifications play a supporting role in DCM management. Moderate sodium restriction helps reduce fluid retention. Taurine supplementation (500–1000 mg twice daily, depending on body weight) is recommended for all dogs with DCM, and is essential for breeds or diets where taurine deficiency may be a contributing factor. L-carnitine supplementation may also be beneficial, though the evidence is less robust. Omega-3 fatty acids (EPA and DHA from fish oil) may help reduce muscle wasting and support heart function. Ensuring adequate caloric intake is important, as cardiac cachexia — severe muscle wasting driven by heart failure — is a common complication. A diet rich in high-quality protein from reputable pet food sources supports muscle maintenance during cardiac illness.

Home Monitoring

Owners play a critical role in managing DCM at home. The single most valuable monitoring tool is the sleeping respiratory rate (SRR). Counting your dog's breaths while they sleep establishes a baseline; any consistent increase above this baseline — or above 30 breaths per minute — may indicate worsening fluid accumulation and warrants veterinary assessment. Monitoring appetite, energy levels, cough frequency, and abdominal girth provides additional early warning of changes.

The prognosis for DCM varies significantly depending on breed, stage at diagnosis, and response to treatment. Understanding what to expect helps owners make informed decisions and plan for their dog's care.

Survival Times by Breed and Stage

Dobermans generally have the most guarded prognosis among DCM-affected breeds. Without treatment, survival after the onset of congestive heart failure in Dobermans is typically only six to eight weeks. With optimal medical management, median survival extends to approximately six to twelve months, though some individuals do better. Other large breeds — such as Great Danes, Irish Wolfhounds, and Newfoundlands — often have somewhat longer survival times, with medians of twelve to twenty-four months after heart failure onset with treatment. Dogs diagnosed in the preclinical stage and started on pimobendan have the best outlook, with some living two to four years or more before progressing to heart failure.

Diet-Associated DCM

Dogs with diet-associated DCM (linked to grain-free or boutique diets) often have the most encouraging prognosis. When the offending diet is changed and taurine supplementation is provided, many of these dogs show significant improvement in heart function — and some experience complete recovery with normalisation of echocardiographic parameters. This underscores the importance of testing taurine levels and taking a thorough dietary history in every DCM case.

Quality of Life Priorities

Living with a dog diagnosed with DCM requires a shift in perspective rather than a loss of hope. Most dogs receiving appropriate treatment feel well for a significant portion of their remaining time. Gentle, regular exercise is generally encouraged — the goal is to keep your dog active without causing exhaustion. Avoid strenuous exercise, excessive heat, and high-altitude environments, which all increase cardiac workload.

Regular veterinary rechecks — typically every three to six months, or more frequently after medication adjustments — allow your veterinary team to fine-tune treatment and catch any deterioration early. Echocardiographic monitoring tracks changes in heart size and function, while blood work ensures kidney function remains stable on heart medications.

Emotional support for owners is also important. A diagnosis of DCM can be distressing, and it helps to know that veterinary cardiology has made enormous strides. Many owners find that their dog's quality of life on treatment exceeds their initial expectations. Supporting your dog's overall health through proper nutrition and comprehensive senior care ensures the best possible outcome.